Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness
Decision on EU marketing authorisation expected for momelotinib by early 2024
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
Subscribe To Our Newsletter & Stay Updated
